SNY vs NVO vs AZN vs NVS vs GSK

For growth investors, AstraZeneca PLC (AZN) is the stronger pick with 8.

6% revenue growth year-over-year, versus 4. 1% for GSK plc (GSK). GSK plc (GSK) offers the better valuation at 6. 7x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate Sanofi (SNY) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GSK plc (GSK) is the cheapest at 6.

7x versus AstraZeneca PLC at 27. 9x. On forward P/E, Novo Nordisk A/S is actually cheaper at 2. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Novo Nordisk A/S wins at 0. 10x versus Novartis AG's 1. 08x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +94.

4%, compared to +2. 5% for Sanofi (SNY). Over 10 years, the gap is even starker: AZN returned +268. 6% versus SNY's +57. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Novartis AG (NVS) is the lower-risk stock at 0.

42β versus Novo Nordisk A/S's 1. 56β — meaning NVO is approximately 267% more volatile than NVS relative to the S&P 500. On balance sheet safety, Sanofi (SNY) carries a lower debt/equity ratio of 30% versus 111% for GSK plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AstraZeneca PLC (AZN) is pulling ahead at 8.

6% versus 4. 1% for GSK plc (GSK). On earnings-per-share growth, the picture is similar: GSK plc grew EPS 348. 4% year-over-year, compared to -7. 3% for Sanofi. Over a 3-year CAGR, NVO leads at 20. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus 16. 7% for Sanofi — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVO leads at 41. 3% versus 13. 6% for SNY. At the gross margin level — before operating expenses — AZN leads at 81. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Novo Nordisk A/S (NVO) is the more undervalued stock at a PEG of 0. 10x versus Novartis AG's 1. 08x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Novo Nordisk A/S (NVO) trades at 2. 1x forward P/E versus 17. 7x for AstraZeneca PLC — 15. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNY: 15. 8% to $50. 00.

All stocks in this comparison pay dividends.

GSK plc (GSK) offers the highest yield at 6. 6%, versus 1. 8% for AstraZeneca PLC (AZN).

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 2. 8% yield, +178. 5% 10Y return). Novo Nordisk A/S (NVO) carries a higher beta of 1. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVS: +178. 5%, NVO: +99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SNY is a mid-cap income-oriented stock; NVO is a large-cap deep-value stock; AZN is a large-cap quality compounder stock; NVS is a large-cap quality compounder stock; GSK is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.